{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:06:55Z","timestamp":1789020415881,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically analyze the clinical characteristics of gut microbiota translocation in patients after acute myocardial infarction (AMI), explore the relationships among intestinal barrier dysfunction, gut microbiota changes, inflammatory response, and cardiac function impairment, and further evaluate its association with short-term prognosis, so as to provide new clinical evidence for risk stratification and comprehensive intervention in AMI patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study adopted a single-center retrospective cohort design. A total of 148 patients with AMI who were hospitalized in the Department of Cardiology of our hospital and received standardized treatment from April 2023 to June 2025 were selected as the study subjects (AMI group), and 110 healthy volunteers who underwent physical examination during the same period were included as the control group. Venous blood and fecal samples had been collected within 24\u2005h after admission or on the day of physical examination as part of the routine clinical laboratory or health examination workflow, and the corresponding laboratory results were retrospectively extracted for this study. Serum D-lactic acid (D-LA), diamine oxidase (DAO), and lipopolysaccharide (LPS) levels were detected by enzyme-linked immunosorbent assay to evaluate intestinal barrier function and microbiota translocation; the quantities of five representative gut microbiota, including Bifidobacterium, Lactobacillus, Bacteroides, Enterobacter, and Enterococcus, were detected by gut microbiota culture. According to serum LPS levels and intestinal barrier indicators, the presence of gut microbiota translocation was comprehensively determined, and patients were divided into a translocation group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952) and a non-translocation group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200996). General clinical data and relevant laboratory indicators were collected, including C-reactive protein (CRP), white blood cell count (WBC), N-terminal pro-brain natriuretic peptide (NT-proBNP), and left ventricular ejection fraction (LVEF). All patients were followed for 90 days after discharge, and newly occurring major adverse cardiovascular events (MACE) during the follow-up period, including heart failure, malignant arrhythmia, recurrent myocardial infarction, and cardiac death, were recorded. Pearson correlation analysis was used to explore the relationships between gut-related indicators and inflammatory indicators as well as cardiac function indicators, and multivariable logistic regression analysis was used to explore factors associated with short-term poor prognosis in patients with AMI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with the control group, serum D-LA, DAO, and LPS levels were significantly increased in the AMI group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Meanwhile, the gut microbiota structure of AMI patients was markedly disturbed, manifested by a significant decrease in putatively beneficial or commensal bacteria, including Bifidobacterium, Lactobacillus, and Bacteroides, and a significant increase in opportunistic\/pathobiont bacteria such as Enterobacter and Enterococcus (P&amp;lt;0.05). Further subgroup analysis showed that, compared with the non-translocation group, the translocation group had more obvious gut microbiota disturbance, characterized by decreased levels of Bifidobacterium, Lactobacillus, and Bacteroides and increased levels of Enterobacter and Enterococcus (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Because D-LA, DAO, and LPS were used to define translocation status, their subgroup differences were not interpreted as independent findings. In addition, CRP, WBC, and NT-proBNP levels were significantly higher in the translocation group than in the non-translocation group, whereas LVEF was significantly lower in the translocation group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Follow-up results showed that the incidence of MACE within 90 d was significantly higher in the translocation group than in the non-translocation group, with the most significant increases observed in acute heart failure and malignant arrhythmia (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Correlation analysis showed that D-LA, DAO, LPS, Enterobacter, and Enterococcus were significantly positively correlated with CRP, WBC, and NT-proBNP levels and significantly negatively correlated with LVEF (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05); Bifidobacterium, Lactobacillus, and Bacteroides were negatively correlated with CRP, WBC, and NT-proBNP and positively correlated with LVEF (P &amp;lt; 0.05). These correlation results remained statistically significant after Benjamini-Hochberg FDR correction. Exploratory multivariable logistic regression analysis suggested that elevated levels of LPS, DAO, and NT-proBNP, decreased LVEF, and increased abundances of Enterobacter and Enterococcus were associated with poor short-term prognosis in patients with AMI (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). However, because only 32 patients experienced at least one MACE, these regression results should be interpreted cautiously because of the limited events-per-variable ratio.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AMI patients exhibit marked intestinal barrier dysfunction and gut microbiota translocation during the acute phase, characterized by elevated levels of D-LA, DAO, and LPS, with concomitant decreases in putatively beneficial or commensal bacteria, including Bifidobacterium, Lactobacillus, and Bacteroides, and increases in opportunistic\/pathobiont bacteria such as Enterobacter and Enterococcus. The degree of gut microbiota translocation is closely associated with enhanced inflammatory response, worsening cardiac function, and the occurrence of short-term adverse cardiovascular events, suggesting that the \u201c gut-heart axis \u201c may play an important role in disease progression and prognostic evolution after AMI. Intestinal barrier function and microbiota translocation-related indicators may serve as potential auxiliary biomarkers for prognostic risk assessment in AMI patients and provide new research directions for future gut microbiota intervention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1890161","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:31:39Z","timestamp":1789018299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics of gut microbiota translocation after acute myocardial infarction and its impact on prognosis"],"prefix":"10.3389","volume":"13","author":[{"given":"JunXiang","family":"Liu","sequence":"first","affiliation":[{"name":"Characteristic Medical Center, Characteristic Medical Center of Chinese People\u2019s Armed Police Force","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DongLin","family":"Song","sequence":"additional","affiliation":[{"name":"Cardiology Department, Tianjin Provincial Corps Hospital of Chinese People\u2019s Armed Police Forces","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yuan","sequence":"additional","affiliation":[{"name":"Characteristic Medical Center, Characteristic Medical Center of Chinese People\u2019s Armed Police Force","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiYing","family":"Sun","sequence":"additional","affiliation":[{"name":"Characteristic Medical Center, Characteristic Medical Center of Chinese People\u2019s Armed Police Force","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuoHong","family":"Yang","sequence":"additional","affiliation":[{"name":"Characteristic Medical Center, Characteristic Medical Center of Chinese People\u2019s Armed Police Force","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jjcc.2022.07.003","article-title":"Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond","volume":"81","author":"Saito","year":"2023","journal-title":"J Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.amjcard.2020.08.031","article-title":"Outcomes of patients with acute myocardial infarction who recovered from severe in-hospital complications","volume":"135","author":"Sawano","year":"2020","journal-title":"Am J Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102884","DOI":"10.1016\/j.ebiom.2020.102884","article-title":"Mitochondria in acute myocardial infarction and cardioprotection","volume":"57","author":"Ramachandra","year":"2020","journal-title":"EBioMedicine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102629","DOI":"10.1016\/j.arr.2024.102629","article-title":"Regulated cell death in acute myocardial infarction: molecular mechanisms and therapeutic implications","volume":"104","author":"Zhu","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1676619","DOI":"10.3389\/fnut.2025.1676619","article-title":"Advances in nutritional interventions for coronary heart disease patients from the perspective of the gut-heart axis","volume":"12","author":"Gao","year":"2025","journal-title":"Front Nutr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","article-title":"Human gut microbiota\/microbiome in health and diseases: a review","volume":"113","author":"Gomaa","year":"2020","journal-title":"Antonie Van Leeuwenhoek"},{"key":"B7","doi-asserted-by":"publisher","first-page":"625913","DOI":"10.3389\/fcimb.2021.625913","article-title":"Role and mechanism of gut Microbiota in human disease","volume":"11","author":"Chen","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.immuni.2024.12.012","article-title":"Microbiota translocation following intestinal barrier disruption promotes mincle-mediated training of myeloid progenitors in the bone marrow","volume":"58","author":"Robles-Vera","year":"2025","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","article-title":"The intestinal microbiota fuelling metabolic inflammation","volume":"20","author":"Tilg","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.hlc.2022.12.006","article-title":"Relationships between systemic inflammation, intestinal damage and postoperative organ dysfunction in adults undergoing low-risk cardiac surgery","volume":"32","author":"Habes","year":"2023","journal-title":"Heart Lung Circ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00380-021-01919-7","article-title":"Prognosis of acute myocardial infarction in patients on hemodialysis stratified by killip classification in the modern interventional era (focus on the prognosis of Killip class 1)","volume":"37","author":"Takasaki","year":"2022","journal-title":"Heart Vessels"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1155\/2020\/3419034","article-title":"D-Lactic acid as a metabolite: toxicology, diagnosis, and detection","author":"Pohanka","year":"2020","journal-title":"Biomed Res Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41430-024-01448-2","article-title":"Measurement of diamine oxidase (DAO) during low-histamine or ordinary diet in patients with histamine intolerance","volume":"78","author":"Rentzos","year":"2024","journal-title":"Eur J Clin Nutr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.ijbiomac.2022.10.024","article-title":"Lentinan inhibits oxidative stress and alleviates LPS-induced inflammation and apoptosis of BMECs by activating the Nrf2 signaling pathway","volume":"222","author":"Meng","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1002\/cph4.70024","article-title":"Microbiota in gut-heart axis: metabolites and mechanisms in cardiovascular disease","volume":"15","author":"Kondapalli","year":"2025","journal-title":"Compr Physiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.3390\/nu15214633","article-title":"Efects of gut Microbiota on hypertension and the cardiovascular system","volume":"15","author":"Li","year":"2023","journal-title":"Nutrients"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e70136","DOI":"10.1002\/ctm2.70136","article-title":"Intestinal oxygen utilisation and cellular adaptation during intestinal ischaemia-reperfusion injury","volume":"15","author":"Archontakis-Barakakis","year":"2025","journal-title":"Clin Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-food-061120-014739","article-title":"Gut colonization mechanisms of Lactobacillus and Bifidobacterium: an argument for personalized designs","volume":"12","author":"Xiao","year":"2021","journal-title":"Annu Rev Food Sci Technol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/CM9.0000000000003617","article-title":"Intestinal dysbiosis and colorectal cancer","volume":"138","author":"Kang","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.3748\/wjg.v28.i30.4053","article-title":"Gut microbiota, inflammatory bowel disease and colorectal cancer","volume":"28","author":"Quaglio","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102649","DOI":"10.1016\/j.ebiom.2020.102649","article-title":"The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions","volume":"52","author":"Tr\u00f8seid","year":"2020","journal-title":"EBioMedicine"},{"key":"B23","first-page":"H1227","article-title":"Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease","volume-title":"Am J Physiol Heart Circ Physiol","author":"Lewis","year":"2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ncomms2266","article-title":"Symptomatic atherosclerosis is associated with an altered gut metagenome","volume":"3","author":"Karlsson","year":"2012","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41467-017-00900-1","article-title":"The gut microbiome in atherosclerotic cardiovascular disease","volume":"8","author":"Jie","year":"2017","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/10799893.2020.1808675","article-title":"Irisin alleviates LPS-induced liver injury and inflammation through inhibition of NLRP3 inflammasome and NF-\u03baB signaling","volume":"41","author":"Li","year":"2021","journal-title":"J Recept Signal Transduct Res"},{"key":"B27","first-page":"390","article-title":"Heart-gut microbiota communication determines the severity of cardiac injury after myocardial ischaemia\/reperfusion","volume-title":"Cardiovasc Res","author":"Zhao","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the heart failure association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijcard.2022.05.054","article-title":"Heart failure with normal LVEF in BIOSTAT-CHF","volume":"364","author":"Baumhove","year":"2022","journal-title":"Int J Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"12465","DOI":"10.3390\/ijms252212465","article-title":"The gut-heart axis: molecular perspectives and implications for myocardial infarction","volume":"25","author":"Rivera","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1002\/imt2.125","article-title":"Gut microbiota in heart failure and related interventions","volume":"2","author":"Chen","year":"2023","journal-title":"Imeta"},{"key":"B32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","article-title":"Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction","volume":"11","author":"Patti","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.53964\/id.2026002","article-title":"Role of gut microbiota in the drug metabolism: a review","volume":"3","author":"Kapoor","year":"2026","journal-title":"Innov Discov"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1890161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:31:40Z","timestamp":1789018300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1890161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2026.1890161"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1890161","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1890161"}}